The effect of long-term amiodarone administration on myocardial fibrosis and evolution of left ventricular remodeling in a porcine model of ischemic cardiomyopathy by unknown
Zagorianou et al. SpringerPlus  (2016) 5:1568 
DOI 10.1186/s40064-016-3249-3
RESEARCH
The effect of long-term amiodarone 
administration on myocardial fibrosis 
and evolution of left ventricular remodeling in a 
porcine model of ischemic cardiomyopathy
Anastasia Zagorianou1, Meletios Marougkas1, Stavros G. Drakos1, Nikolaos Diakos1, 
Panagiotis Konstantopoulos2, Despina N. Perrea2, Maria Anastasiou‑Nana1 and Konstantinos Malliaras1*
Abstract 
Amiodarone is effective in suppressing arrhythmias in heart failure patients. We investigated the effect of long‑term 
amiodarone administration on myocardial fibrosis and left ventricular (LV) remodeling in a porcine model of ischemic 
cardiomyopathy. Eighteen infarcted farm pigs were randomized to receive long‑term amiodarone administration 
for 3 months (n = 9) or conventional follow‑up (n = 9). Evolution of LV remodeling over 3 months post‑myocardial 
infarction was examined at tissue level (myocyte size, myocardial fibrosis and vascular density assessed by whole‑field 
digital histopathology), organ level (LV structure and function assessed by echocardiography), and systemic level (BNP 
and MMP‑9 levels). Long‑term administration of the standard anti‑arrhythmic doses of amiodarone was not associ‑
ated with adverse effects on myocardial fibrosis and other features of adverse cardiac remodeling. This favorable 
safety profile suggests that long‑term anti‑arrhythmic therapy with amiodarone warrants further clinical investigation 
in the subpopulation of heart failure patients with significantly increased burden of arrhythmias.
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Background
Left ventricular (LV) remodeling is a complex pathophys-
iologic process characterized by changes at molecular, 
cellular and tissue level (Dixon and Spinale 2011). These 
changes result in cardiac dilatation and deterioration of 
LV function, and contribute to the onset and progres-
sion of heart failure (Pfeffer and Braunwald 1990). Ami-
odarone is an anti-arrhythmic drug that has proven to 
be effective in suppressing arrhythmias in heart failure 
patients, without increasing sudden cardiac death (Bardy 
et al. 2005). However, the impact of chronic amiodarone 
therapy on myocardial fibrosis and adverse LV remode-
ling remains unclear (Djandjighian et al. 2000; Tachikawa 
et  al. 2005; Hu et  al. 2004; Massie et  al. 1996; Cleland 
et al. 1987; Hirasawa et al. 2009). We therefore sought to 
investigate the safety and efficacy of long-term amiodar-
one administration in a porcine model of ischemic cardi-
omyopathy. Given that amiodarone is known to promote 
interstitial pulmonary fibrosis (Jackevicius et  al. 2011; 
Schwaiblmair et al. 2010; Papiris et al. 2010), the effect of 
chronic amiodarone administration on myocardial fibro-
sis was one of the main focuses of our investigation.
Methods
Surgical procedures and animal follow‑up
A total of 18 farm pigs weighing ~30  kg were used in 
this experimental study. The experimental protocol was 
approved by the Veterinary Service of Athens and the 
ethical committee of the University of Athens, in accord-
ance with national and EU legislation.
Animals were pre-anesthetized by intramuscular 
administration of ketamine (15–20  mg/kg), midazolam 
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(0.5  mg/kg) and atropine (0.05  mg/kg). Auricular vein 
catheter placement was followed by induction of anes-
thesia with propofol (2  mg/kg). After induction of 
anesthesia, animals underwent transthoracic contrast 
echocardiography (Sonos 5500, Philips) and collection of 
blood samples. This was followed by endotracheal intu-
bation and mechanical ventilation. All animals received 
mixtures of atmospheric air and oxygen (FiO2  =  30  %) 
with a tidal volume of 10–15 ml/kg of body weight and a 
respiratory frequency of 15/min. Throughout the experi-
ment animals received intravenous infusion of propofol 
10 mg/kg/h, fentanyl 20 g/kg and cisatracurium 0.2 mg/
kg/20  min. The heart was accessed by lateral thoracot-
omy and myocardial biopsies were procured from the 
base of the LV. Afterwards, animals underwent induc-
tion of acute myocardial infarction (AMI) by permanent 
ligation of the left anterior descending coronary artery 
distal to the 1st diagonal branch, followed by closure of 
the chest. Animals were randomized into two groups: 
(a) animals in Group 1 (n = 9) received a loading dose of 
amiodarone (20 mg/kg IV during AMI) followed by daily 
p.o. administration of amiodarone (600 mg daily during 
the first 5 days post-MI, 300 mg daily during the follow-
ing 3  months); (b) animals in Group 2 (control group, 
n = 9) underwent conventional follow-up. Animals were 
followed for 3  months. One month post-MI animals 
underwent transthoracic contrast echocardiography 
and collection of blood samples. Three months post-MI, 
animals underwent transthoracic contrast echocardiog-
raphy, collection of blood samples and procurement of 
myocardial biopsies from the base of the LV and heart 
explantation. The explanted heart was sectioned into 
1-cm-thick short-axis slices. Each slice was photographed 
with a digital camera, and infarct size was determined as 
the percentage of LV by manual tracing by a researcher 
blinded to treatment allocation.
Histochemical stains and immunocytochemistry
Myocardial tissue immediately after its excision was fixed 
in 10  % buffered formalin and dehydrated in increasing 
concentrations of alcohol, then cleared through xylene 
and subsequently embedded in paraffin. The tissue sec-
tions were cut in 4-μm sections, collected and mounted 
on glass slides and prepared for various histochemical 
stains and immunohistochemistry.
Masson’s trichrome Masson’s trichrome stain was used 
for collagen content evaluation. The stain was performed 
as previously described (Drakos et al. 2010).
Periodic acid Schiff stain reaction (PAS) PAS stain 
reaction was used to evaluate cardiac myocyte size. The 
reaction is based on oxidation of certain tissue elements 
to aldehydes by periodic acid. The stain was performed 
as previously described (Drakos et  al. 2010). PAS was 
selected for cardiomyocyte size evaluation because it 
offers sufficient cardiomyocyte basement membrane 
visualization.
CD34 immunostaining Microvasculature evaluation 
was performed with immunostaining for endothelial 
cell protein CD34 using a mouse monoclonal anti CD34 
antibody (Dako, Carpinteria, California). Immunohisto-
chemistry experiments were performed using a peroxi-
dase-conjugated streptavidin–biotin system and diam-
inobenzidine as a substrate. To achieve a high degree of 
reproducibility we avoided manual staining. Histochemi-
cal stains were performed using the automatic Artisan 
Special Stains System (Dako, Carpinteria, California) and 
the immunohistochemistry experiments were performed 
on the Autostainer (Dako, Carpinteria, California).
Whole‑field digital microscopy Advanced digital 
microscopy allowed examination of the entire heart tissue 
areas from the epicardium to the endocardium (Fig. 1), as 
described previously (Drakos et  al. 2010). Whole-slide 
images were analyzed with the ScanScope XT system 
equipped with the ImageScope 10.0 image analysis algo-
rithms (Aperio Technologies, Vista, California).
Interstitial fibrosis evaluation We set the staining color 
threshold of the ImageScope 10.0 colocalization analysis 
algorithm to accurately identify collagen on the basis of 
its blue color as previously described (Drakos et al. 2010). 
Myocardial fibrosis was defined as the collagen con-
tent in the interstitial spaces and endomysial/perimysial 
spaces, including the collagen content around capillaries 
and vessels (expressed as % of total tissue analysis area).
Microvasculature evaluation We used the ImageScope 
10.0 microvessels analysis algorithm to distinguish 
endothelial cells from nonspecific staining of tissue by 
applying appropriate dark and light thresholds as previ-
ously described (Drakos et  al. 2010). Only myocardial 
sections oriented in cross-section were analyzed. Micro-
vascular density was defined as “microvessels/0.1 mm2”.
Cardiomyocyte size evaluation Cardiomyocytes (40× 
magnification) were accepted for size measurement if 
they met the following criteria: (a) cellular cross-sections 
present (b) visible and round shaped nuclei located close 
to the cell center and (c) intact cellular basement mem-
branes, as described previously (Drakos et al. 2010). The 
cross section area of 100 selected cardiomyocytes per 
sample was calculated by our digital histopathology sys-
tem and then averaged.
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Assessment of the levels of circulating BNP and MMP9
The levels of circulating BNP and MMP9 were measured 
as biochemical markers of adverse remodeling (Fertin 
et  al. 2012) at baseline and at 1 and 3  months post-MI. 
BNP and MMP9 concentration was measured in serum 
samples with the ELISA method, using commercially-
available kits (USCN Life Science Inc).
Statistical analysis
Continuous variables are presented as mean ± standard 
deviation. Normality of data was verified by the Kolmog-
orov–Smirnov test. Differences between the two groups 
were tested using independent samples t test. All tests 
were 2-sided. No multiplicity adjustment for multiple 




Nine animals were randomized to the amiodarone group 
and 9 animals to the control group. Six animals (four ran-
domized to the control group and two to the amiodarone 
group) died during induction of AMI due to arrhythmia. 
One animal (randomized to the amiodarone group) died 
1  week post-MI (due to surgical wound infection), and 
one (randomized to the amiodarone group) due to pul-
monary edema. Five animals in each group completed 
the 3-month follow-up and were included in the analysis.
Echocardiography
Absolute values of echocardiography-measured parame-
ters are provided in Table 1. No differences were observed 
between groups at baseline and 1 month post-MI. Three 
months post-MI, animals randomized to the amiodar-
one group had significantly lower LV end-diastolic diam-
eter compared to control animals (53.8  ±  4.0  mm vs. 
60.0 ± 2.8; p = 0.029). No differences in LV end-systolic 
diameter and LV fractional shortening were observed at 
3 months-post-MI between groups.
Histology
Macroscopic histological assessment of infarcted tissue 
did not reveal any morphometric differences between 
the two groups; infarct size (5.33 ± 0.57 % of LV in the 
amiodarone group vs. 5.33 ± 1.52 % of LV in the control 
group, p = 1.0) and infarct circumference (9.66 ± 4.5 % 
of LV circumference in the amiodarone group vs. 
9.0 ± 1.7 % of LV in the control group, p = 0.823) were 
similar between groups. Microscopic histological assess-
ments of cardiomyocyte size, vascular density and myo-
cardial fibrosis are provided in Table 2. No differences in 
myocardial fibrosis, cardiomyocyte size, vascular density 
and myocardial fibrosis were observed between groups. 
Figure  1 shows representative Masson’s trichrome-
stained slices from a treated and a control animal, and 
depicts the absolute change in myocardial fibrosis in the 
amiodarone (+3.2  ±  4.7  % of the LV) and the control 
Fig. 1 Chronic amiodarone administration post‑myocardial infarction is not associated with increased myocardial interstitial fibrosis. Representa‑
tive Masson’s trichrome‑stained slides from an experimental animal randomized to receive chronic amiodarone administration (top) and a control 
animal (bottom). The absolute change in myocardial interstitial fibrosis (expressed as % of myocardium) between baseline (induction of myocardial 
infarction) and 3 months post‑myocardial infarction is presented on the right. No increase in myocardial interstitial fibrosis was observed in animals 
receiving long‑term amiodarone administration, compared to control animals
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group (+9.3 ±  10.7  % of the LV) between baseline (MI 
creation) and 3  months post-MI; no significant differ-
ences (p = 0.291) were observed between groups.
Levels of circulating BNP and MMP9
The levels of circulating BNP and MMP9 were measured 
as biochemical markers of adverse cardiac remodeling 
(Fertin et al. 2012) and are provided in Table 3. No dif-
ferences were observed between groups at any timepoint.
Discussion
Amiodarone is an anti-arrhythmic drug with proven effi-
cacy in suppressing arrhythmias in heart failure patients, 
without increasing sudden cardiac death (Bardy et  al. 
2005). However, the impact of chronic amiodarone 
administration on the evolution of adverse LV remod-
eling requires further investigation, as experimental and 
clinical studies to date have yielded conflicting results 
(Djandjighian et al. 2000; Tachikawa et al. 2005; Hu et al. 
2004; Massie et  al. 1996; Cleland et  al. 1987; Hirasawa 
et al. 2009). In addition, the effect of chronic amiodarone 
administration on myocardial fibrosis remains unclear; 
this issue merits further investigation, given that ami-
odarone is known to exert profibrotic effects in the lung 
parenchyma (Jackevicius et al. 2011; Schwaiblmair et al. 
2010; Papiris et al. 2010). We therefore sought to investi-
gate the effects of long-term amiodarone therapy on LV 
remodeling and myocardial fibrosis in a clinically-rele-
vant model of ischemic cardiomyopathy.
We found that chronic amiodarone administration has 
no significant effect—either positive or negative—on the 
evolution of LV remodeling post-MI at the tissue (myo-
cyte size, vascular density and interstitial fibrosis), organ 
(LV structure and function) and systemic level (levels of 
circulating BNP and MMP-9). While LV dilatation (as 
assessed by echocardiographic measurement of LVEDD) 
was attenuated in animals receiving amiodarone, this was 
not accompanied by concomitant beneficial changes in 
histological and biochemical indices of remodeling. In 
Table 1 Echocardiographic assessment of  cardiac struc-
ture and function
p value in italics indicates statistical significant differences between groups
LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic 
diameter, LVFS left ventricular fractional shortening
Echocardiographic 
parameters
Group Mean ± SD p value
LVEDD (time 0) Amiodarone 36.2 ± 1.6 mm 0.117
Control 38.1 ± 1.8 mm
LVESD (time 0) Amiodarone 26.4 ± 3.2 mm 0.973
Control 26.3 ± 2.0 mm
LVFS (time 0) Amiodarone 27 ± 8 % 0.363
Control 31 ± 3 %
LVEDD (1st month) Amiodarone 47.7 ± 4.1 mm 0.591
Control 46.3 ± 2.4 mm
LVESD (1st month) Amiodarone 36.3 ± 2.5 mm 0.163
Control 31.4 ± 5.7 mm
LVFS (1st month) Amiodarone 23 ± 4 % 0.162
Control 33 ± 11 %
LVEDD (3rd month) Amiodarone 53.8 ± 4.0 mm 0.029
Control 60.0 ± 2.8 mm
LVESD (3rd month) Amiodarone 39.7 ± 4.1 mm 0.180
Control 44.9 ± 5.7 mm
LVFS (3rd month) Amiodarone 26 ± 5 % 0.868
Control 25 ± 10 %
Table 2 Histological assessment of  myocyte size, vessel 
density and myocardial fibrosis
Histological parameters Group Mean ± SD p value
Myocyte size (baseline) (μm2) Amiodar‑
one
326.24 ± 58.30 0.197
Control 264.60 ± 71.70




150 ± 100 0.073
Control 340 ± 90




8.44 ± 7.21 0.839
Control 9.48 ± 5.57
Myocyte size (3 months) (μm2) Amiodar‑
one
638.22 ± 259.70 0.874
Control 607.31 ± 245.06




150 ± 100 0.150
Control 310 ± 100




11.60 ± 2.98 0.474
Control 16.43 ± 14.12
Table 3 Levels of circulating BNP and MMP9
Biochemical 
parameters
Group Mean ± SD p value
BNP (baseline) Amiodarone 460.19 ± 489.93 pg/ml 0.345
Control 206.89 ± 71.94 pg/ml
MMP9 (baseline) Amiodarone 3508.44 ± 964.32 ng/ml 0.387
Control 4832.00 ± 3073.02 ng/ml
BNP (1 month) Amiodarone 242.59 ± 171.63 pg/ml 0.066
Control 51.21 ± 26.65 pg/ml
MMP9 (1 month) Amiodarone 4363.77 ± 2404.90 ng/ml 0.406
Control 6443.99 ± 4575.34 ng/ml
BNP (3 months) Amiodarone 341.90 ± 285.81 pg/ml 0.447
Control 202.05 ± 216.96 pg/ml
MMP9 (3 months) Amiodarone 9181.24 ± 5077.68 ng/ml 0.714
Control 7681.73 ± 6773.95 ng/ml
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addition, since amiodarone is known to exert anti-beta 
adrenergic effects (Polster and Broekhuysen 1976; Nokin 
et  al. 1983; Chatelain et  al. 1995) (and given the fact 
that beta blockers were not administered in neither the 
treated nor the control group), we cannot rule out that 
the observed attenuation of LV dilation may be induced 
by the beta-blockade effect of amiodarone. Impor-
tantly, from a safety standpoint, no increase in myocar-
dial fibrosis was observed after long-term amiodarone 
administration.
Conclusions
Long-term experimental oral administration of ami-
odarone in doses similar to the ones used in the clinical 
setting was not associated with adverse effects on myo-
cardial fibrosis and other features of adverse cardiac 
remodeling. Given the promising results of amiodarone 
effectiveness in suppressing cardiac arrhythmias, these 
new safety findings suggest that anti-arrhythmic therapy 
with amiodarone warrants further clinical investiga-
tion in the subpopulation of heart failure patients with 
increased burden of supraventricular or life-threatening 
ventricular arrhythmias.
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